Prostate Cancer
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
October 30, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
October 30, 2023
Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needles.
October 30, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
October 30, 2023
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
October 30, 2023
Clarity and PSI Kick Off SAR-bisPSMA Phase III
October 27, 2023
Novartis Confirms Unconstrained Supply for Pluvicto® and Continues to Significantly Expand the Number of Treatment Centers
October 27, 2023
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.
October 27, 2023
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials.
October 27, 2023
The long tail of oncogenic drivers in prostate cancer.
October 27, 2023
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.
October 27, 2023
Reliable Prostate Cancer Risk Mapping from MRI Using Targeted and Systematic Core Needle Biopsy Histopathology.
October 26, 2023
Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review.
October 26, 2023